

Cumulative Index 1989

Volume 7

February	HEART FAILURE, pages 1-208
May	UPDATE IN PEDIATRIC CARDIOLOGY, pages 209-482
August	CARDIAC IMAGING, pages 483-737
November	CORONARY ANGIOPLASTY, pages 739-934

Note: Page numbers for complete issues and article titles are in **boldface** type.

ACE. See *Angiotensin-converting enzyme*.
Adenosine, for arrhythmias, in infants and children, 312-313
ADH. See *Antidiuretic hormone*.
Allograft rejection, detection of, antimyosin imaging in, 583
in heart transplantation in children, 414-415
Amiodarone, for ventricular and supraventricular arrhythmias, in infants and children, 307-308
for ventricular arrhythmias, 159-160
Amrinone, for CHF, 137-138
ANF. See *Atrial natriuretic factor*.
Angioplasty, coronary, evolution of, **739-742**
issue on, 739-923. See also *Percutaneous transluminal coronary angioplasty*.
Angiotensin-converting enzyme (ACE) inhibition, effect on survival, 124-125
in heart failure, 119-130
regional blood flow response to, 123
renal and electrolyte response to, 123-124
Angiotensin-converting enzyme inhibitors, adverse effects of, 126-127
clinical efficacy of, 124
hemodynamic effects of, 122-123
mechanism of action of, 121
pharmacology of, 121-122
Antiarrhythmic drugs, for CHF, 156-161
principles regarding use of, 154-156
Anticoagulants, in prevention and treatment of restenosis, 858
Antidiuretic hormone (ADH), release of, in heart failure, 52, 57
Antimyosin, radiolabeled, in detection of cardiac myocardial necrosis, 578-583
in detection of cardiac transplant rejection, 583
in myocardial infarction, 580-582
in myocarditis, 582-583
Antithymocyte globulin (ATG), for prevention of allograft rejection in cardiac transplantation, 190
Aortic aneurysms, abdominal, evaluation of, NMR imaging for, 635
thoracic, detection of, NMR imaging for, 635
Aortic dissection, diagnosis of, NMR imaging for, 635
Aortic regurgitation, assessment of, by Doppler echocardiography, 487-489
in Kawasaki syndrome, 455
Aortic stenosis, assessment of, by Doppler echocardiography, 483-484
Aortic valve area, calculation of, by Doppler echocardiography, 484-487
Aortic valve disease, assessment of, by Doppler echocardiography, 483
Aortocoronary saphenous vein bypass grafts, obstructed, TBA for, 764-769
Arrhythmias, in CHF, drugs for, 156-161
management of, 145-169
nonpharmacologic therapy for, 161-162
in children, cause of, 300
mechanisms of, 302-303
pharmacologic intervention in, 299-318
surgical treatment of, 319-329
supraventricular, in infants and children, drugs for, 309-312
ventricular, in infants and children, drugs for, 303-304
ventricular and supraventricular, in infants and children, drugs for, 305-309
Arterial circulation, mechanical properties of, 30. See also *Circulation, arterial*.
Arteries, coronary, atherosclerotic, in TBA patients, 749-764. See also *Coronary atherosclerosis*.
calcification in, ultrafast CT scanning for detection of, 727-729
Arteritis, evaluation of, NMR imaging for, 635
Aspirin, in prevention and treatment of restenosis, 857-858
in treatment of acute myocardial infarction, 833-834
in treatment of Kawasaki syndrome, 458
Atherectomy, in prevention and treatment of restenosis, 859
Atherosclerosis, coronary, in children, 467-468
Atresia, pulmonary, before and after Fontan procedure, 446-447

Atresia (Continued)

- tricuspid, before and after Fontan procedure, 446-447
- in infants with congenital heart disease, management of, 434
- Atrial flutter, surgery for, in children, 328
- Atrial natriuretic factor (ANF), release of, in heart failure, 52-53, 58-59
- Atrial natriuretic peptide, for chronic CHF, 114
- Atrial septal defect, operated on, long-term follow-up of, 915-916
- Atrial septal defects, closure of, 362-365
- Atrioventricular canal, operated on, long-term follow-up of, 917
- Atrioventricular septal defects, complex, anatomical and surgical considerations of, 399-402
- definition of, 399
- diagnosis of, 402
- surgical treatment of, 399-410
 - in current era, 402-403
 - results of, 407-408
 - procedure for, 403-407
- Automatic implantable cardioverter defibrillator (AICD), for management of arrhythmias, 162
- Azathioprine, for prevention of allograft rejection in cardiac transplantation, 189

Balloon angioplasty, transluminal, pathology of, 749-770.

See also *Percutaneous transluminal coronary angioplasty*.

- Balloon valvuloplasty, for valvar pulmonary stenosis, in children, 331-335
- complications of, 333-334
- follow-up procedures, 334-335
- procedure for, 332
- results of, 332-333
- Bernoulli equation, 272
 - for evaluation of interventricular systolic pressure, 279
 - for evaluation of peripheral arterial stenosis, 283-285
 - for evaluation of subvalvar aortic stenosis, 282
 - for evaluation of tricuspid regurgitation, 277
- Beta-adrenergic agonists, in heart failure, 131-134
 - oral therapy with, 134-135
 - and phosphodiesterase inhibitors, combined administration of for CHF, 140
- Beta-adrenergic blockers, for heart failure, 174-179
 - clinical studies of, 176-178
 - multicenter randomized trial, 178-179
 - patient selection and drug titration for, 179
 - for supraventricular arrhythmias, in infants and children, 311-312
 - for treatment of acute myocardial infarction, 833-834
 - for ventricular arrhythmias, 160
- Beta-adrenergic pathway, regulation of, in CHF, 135-136
- Beta-adrenergic receptors, spare, in CHF, 136
- Bleeding, caused by thrombolytic agents in treatment of acute myocardial infarction, 832-833
- Blood flow, myocardial, measurements of, ultrafast CT scanning for determination of, 716-717
- quantitation of, Doppler ultrasound for, 265-269
- to skeletal muscle, methods of measuring, 63-64
- Blood pool scintigraphy, 537-563
 - advantages of, 558
 - clinical applications of, 558
 - equilibrium, 539-543
 - absolute volume calculation in, 544-546
 - disadvantages of, 559
 - first-pass, 537-539
 - high-dose approach, 538-539
 - low-dose approach, 537-538
- parameters generally evaluated by, 546-547
- for parametric imaging, 549-555
- probe used in, 544
- for quantitation of regurgitant index, 547-549
- for right ventricular assessment, 543
- Blood pressure, elevation of, in children, and coronary heart disease, 468
- stress and, 470-472
- family studies of, in management of family at risk for coronary heart disease, 470
- tracking of, in management of family at risk for coronary heart disease, 469-470
- Bretylium, for ventricular arrhythmias, 161

C-11 acetate, for evaluation of myocardial metabolism, 611

C-11 palmita, for evaluation of myocardial metabolism, 611

CABG surgery. See *Coronary artery bypass graft surgery*.

Calcium, cytosolic, control of, effects of maturation on, 218-219

Calcium channel antagonists, in prevention and treatment of restenosis, 858

for ventricular arrhythmias, 160-161

Capillary growth, pathologic, and remodeling, 20

physiologic, and remodeling, 18

Captopril, in treatment of acute myocardial infarction, 834

Cardiac anatomy, ultrafast CT scanning for definition of, 727

Cardiac contractility, maturation and, 209-225

- acquisition of transverse tubular system in, 220-221
- control of cytosolic calcium in, 218-219
- effect of cell organization and myofibrils on, 211-213
- role of contractile proteins in, 214-218
- role of cytoskeleton in, 213-214
- role of sarcoplasmic reticulum in, 219-220

Cardiac disease, peripheral manifestations of, MRS for, 707-709

Cardiac energy metabolism, effects of ischemia on, 697-698

Cardiac fibroblast growth, pathologic, and remodeling, 20-22

- and remodeling, 18-19

Cardiac function, assessment of, by Doppler echocardiography, 483-491

Cardiac imaging, issue on, 483-743

- new radionuclide agents for, 589-605

Cardiac rejection, of the transplanted heart, 188-189

- diagnosis of, 191

Cardiac reserve, in assessment of severity of cardiac failure, 34

- clinical assessment of, 34-36

Cardiac transplantation, cardiac assist devices as bridge to, 201-202

- for heart failure, 183-194
 - complications of, 191-193
 - donor characteristics, 186
 - donor criteria in, 185
 - donor-recipient matching in, 185-186
 - historical background, 183-184
 - immunosuppression in, clinical application of, 188-190
 - patient selection in, 184-185
- perioperative and postoperative care of transplant patient, 188
- recipient characteristics, 185
- rejection of transplanted heart, diagnosis of, 191

supportive care of donor and preservation of donor heart in, 186
 TAH as bridge to, 193
 orthotopic, operative technique, 186-188

Cardiomyopathy (ies), evaluation of, MRS for, 703
 ischemic versus nonischemic, determination of, PET for, 615-616

Cardiopulmonary bypass, percutaneous, in high-risk angioplasty, 865-875
 clinical experience, 869-872
 disadvantages of, 874
 equipment used in, 867-868
 future directions, 874
 hemodynamic changes observed during, 868
 historical background, 866-867
 indications for, 872
 management of patients, 868-869
 technique of, 866-867

Cell culture systems, in pulmonary vascular bed, 908-910

Centrifugal pumps, external, for cardiogenic shock patients, 197

Chamber contractility, assessment of, pressure-volume loop in, 27-29

CHF. See *Congestive heart failure*.

Cigarette smoking, in adolescents, behavioral aspects of, 474-475
 effect on family at risk for coronary heart disease, 472-473

Cine magnetic resonance imaging, 651-659
 compared with other cardiac imaging techniques, 656
 for detection of left ventricular wall stress, 655-656
 for detection of signal loss, 654
 for detection of valvular regurgitation, 654-655
 for evaluation of global left ventricular dimensions and function, 652
 for evaluation of regional myocardial function, 652-654
 technique of, 651-652

Cine MRI. See *Cine magnetic resonance imaging*.

Ciprofloxacin, in prevention and treatment of restenosis, 858

Circulation, arterial, coupling of ventricle with, 30-32
 mechanical properties of, 30
 peripheral, 63-71
 abnormality of, in CHF, 64-66
 central, limitations of, to exercise capacity, 63
 interaction with sympathetic nervous system, 67-69

Circulatory assist devices, future directions for, 203
 indications for, 199-202
 management of, for cardiogenic shock patients, 195-204
 patient selection for, 195-196
 types of, 196-199

Coarctation, of aorta, in infants with congenital heart disease, management of, 432-433
 percutaneous balloon angioplasty of, 346-347
 pulsed Doppler ultrasound for, 287-288

Coarctation imaging, 261

Colchicine, in prevention and treatment of restenosis, 859

Computed tomography (CT), ultrafast, 713-734
 for blood flow measurement, 716-717
 for calculation of left and right ventricular volumes, 724-725
 for calculation of regional myocardial perfusion, 718-723
 cardiac border definition in, for determination of left ventricular mass, 723-724
 for characterization of left ventricular diastolic function, 729-733
 for coronary artery bypass graft patency, 715-716
 for data analyses, 715

for defining cardiac anatomy and pathology, 727
 for detection of calcification in coronary arteries, 727-729
 for determination of basic flow algorithm, 718
 for evaluation of myocardial perfusion, 717-718
 indications for use, 714-715
 interventional, 725-726

Computed tomography (CT) scanner, ultrafast, design and operation of, 714

Congenital heart defects, catheter closure of, 351-368
 surgical treatment of, cardiac dysfunction following, causes of, 439-440
 clinical assessment of ventricular function following, 439-452

Congenital heart disease, Doppler flow studies in, 252
 in infants, atrial ventricular canal defects in, management of, 433
 low cardiac output in, management of, 430-432
 management strategies for, 429-436
 perioperative care for, 419-438
 postoperative assessment of, 420-423
 postoperative complications, 435-436
 postoperative monitoring of, 423-429
 heart rate, pressure, and flows, 425-427
 metabolic function, 429
 respiratory function, 427-428
 urine output, 428-429

preoperative assessment of, 419

tetralogy of Fallot in, management of, 433
 transposition of the great arteries in, management of, 433-434

tricuspid atresia in, management of, 434
 ventricular septal defects in, management of, 433

NMR imaging for, 636-637
 operated on, long-term follow-up of, 915-923
 pediatric, color flow mapping in, 255-264
 turbulent flow in, 262

Congestion, of lung, pathophysiology of, 39-48
 pulmonary vascular, 39

Congestive heart failure (CHF), antiarrhythmic drugs for, 156-161
 arrhythmias in, management of, 145-169
 impaired vascular function in, mechanisms for, 64-66
 in Kawasaki syndrome, 455
 management of, diuretics for, 87-97. See also *Diuretics, for management of CHF*.
 neurotransmitter and hormonal systems in, 73-81
 confounding factors in, 81-82
 pathogenesis of, neurohormonal influences in, 73-86
 primary vascular abnormality in, evidence of, 64
 role of kidney in, 81
 therapy for, 69-70
 vasodilators for, 110-115

Contractility, myocardial, definition of, 12-14

Contrast echocardiography, myocardial, 507-508

Coronary artery bypass graft patency, ultrafast CT scanning for determination of, 715-716

Coronary artery bypass surgery, for Kawasaki syndrome, 460
 in patients with left ventricular dysfunction, operative mortality of, 819-822

PTCA for patients with previous, 791-803
 angioplasty data, 793, 799
 clinical characteristics, 792-793, 799
 complications of, 793, 797, 799-800
 follow-up data, 792-794, 798, 800-801
 life-table analysis, 794, 801
 patient evaluation, 791-792
 patient selection, 791

Coronary artery disease. *See also Coronary heart disease.*
 detection of, PET for, 612
 following heart transplantation in children, 415-416
 ultrafast CT scanning in, 713-734

Coronary artery ectasia, in Kawasaki syndrome, 455-456

Coronary artery flow reserve, assessment of, PET for, 612-613

Coronary atherosclerosis, in TBA patients, 749-764
 early changes, 749-750
 intimal fibrous proliferation in, 752-753
 late changes, 750-753

Coronary heart disease, as cause of cardiac failure, 4
 family at risk for, effect of cigarette smoking on, 472-473
 elevated blood pressure in, 468
 hypertension in, 469
 management of, 467-477
 family studies of blood pressure in, 470
 tracking of blood pressure in, 469-470
 preventive strategies for, 473-474
 socioeconomic background of, 473

TBA for, pathology of, 749-770

Corticosteroids, for prevention of allograft rejection in cardiac transplantation, 189-190

Cyclosporine, for prevention of allograft rejection in cardiac transplantation, 190

Cytoskeleton, effect of maturation on, and cardiac contractility, 213-214

Diabetes, and cardiac failure, 4

Diastolic dysfunction, definition of, 14

Digitalis, in heart failure, 99-103
 clinical applications of, 100-103
 for supraventricular arrhythmias, in infants and children, 309-311

Digoxin, for chronic heart failure, 101-103

Dipyridamole, for Kawasaki syndrome, 459
 in prevention and treatment of restenosis, 857

Disopyramide, for ventricular arrhythmias, 159

Diuretics, for management of CHF, 87-97
 combination therapy, 92-94
 complications of, 94-95
 factors influencing action of, 90-91
 moderate agents, 90
 potent agents, 90
 rotation of, 91-92
 site of action of, 87
 specific agents, 88-90
 weak agents, 88-90

Dobutamine, for acute myocardial infarction, 100-101
 in heart failure, 132-134

Dopamine, in heart failure, 131-132

Doppler catheters, 525-530
 clinical feasibility of, 526-527
 future directions of, 528-530

Doppler color flow mapping, in evaluation of fetal circulation, 242-243, 262-263
 in pediatric cardiology, 255-264
 application of, 260-262
 real time, 256-260
 calculation and color assignment in, 257
 color aliasing in, 257-260
 color variance display in, 260
 sampling in, 256-257

Doppler echocardiography, for assessment of anatomy and cardiac function, 483-491
 for assessment of atrioventricular valve stenosis, 276
 for assessment of diastolic performance, 489-490
 for assessment of right ventricular or pulmonary artery pressure, 276-282
 for assessment of semilunar valve stenosis, 273-276
 for calculation of pressure drop, 272-285
 in diagnosis of pediatric heart disease, 265-297

Doppler flow studies, in congenital heart disease, 252
 of fetal circulation, 239-253
 cardiovascular applications, 247-252
 with continuous wave Doppler, 239-240
 distribution of organ flow, 243
 fetal vessels assessment, 246-247
 flow calculations, 243
 pressure gradients, 243
 with pulsed Doppler, 240-242
 uteroplacental assessment, 243-246
 velocity and direction indicators, 243

Doppler measurements, clinical utility of, 527-528

Doppler ultrasound, pulsed, in coarctation, 287-288
 in patent ductus arteriosus, 285-287

Drug infusion devices, implantable, for management of arrhythmias, 162

Drugs, antiarrhythmic. *See Antiarrhythmic drugs.*

Dynamic Spatial Reconstructor (DSR), 714

Dysplasia, arrhythmogenic right ventricular, surgery for, in children, 325-326

Dyspnea, effect on lung function, 40-41

ECG-LVH, and cardiac failure, 5-6

Echocardiography. *See specific types, e.g., Doppler, Stress.*

Edema, in heart failure, 49
 pulmonary, effect on lung function, 39-40

Eicosanoids, in heart failure, 57-58
 activation of, 53

Ejection fraction, and failing heart, 26

Electrocardiogram (ECG), abnormalities of, and cardiac failure, 5-6

Electrophysiologic matrix, concept of, corollaries of, 146

Encainide, for ventricular and supraventricular arrhythmias, in infants and children, 307
 for ventricular arrhythmias, 159

Enoximone, for CHF, 139

Excitability, altered, clinical definition of, 146-152
 hypothesis of, 145-146

Exercise, evaluation of, blood pool scintigraphy for, 555-558
 global left ventricular performance during, evaluation of, 501-504
 in heart failure, contrasting ventilatory and gas exchange patterns during, 46-47
 excessive ventilation during, 41-44
 peripheral vasculature conditioning in, 66-67

Exercise capacity, central peripheral limitations to, 63

Exercise echocardiography. *See Stress echocardiography.*

Exercise electrocardiography, for detection of myocardial ischemia, 565-568
 in asymptomatic subjects, 565-567
 in asymptomatic subjects recovering from acute myocardial infarction, 568
 in stable symptomatic patients, 567-568

Exercise stress, assessment of, 499-500

F-18 2-deoxyglucose, for evaluation of myocardial metabolism, 611-612

Felodipine, for chronic CHF, 114

Fetal circulation, noninvasive Doppler evaluation of, 239-253. *See also Doppler flow studies, of fetal circulation.*

Fibrosis, pulmonary, effect on lung function, 40

First harmonic analysis, blood pool scintigraphy for, 549-555

Fish oil, in prevention and treatment of restenosis, 859

Flecainide, for ventricular and supraventricular arrhythmias, in infants and children, 306-307
for ventricular arrhythmias, 159

Fontan operation, lesions requiring, long-term follow-up of, 920

Fontan procedure, modified, for hypoplastic left heart syndrome, 383-384
tricuspid and pulmonary atresia before and after, 446-447

Frank-Starling relationship, effect of development on, 211

Furosemide, for diuretic therapy in CHF, 91-92

Gamma globulin intravenous, for Kawasaki syndrome, 458-459

Gd-DTPA, for detection of acute myocardial infarction, 689-691
for detection of myocardial ischemia, 688-689

Global left ventricular function, analysis of during stress echocardiography, 500-501
cine MRI for, 652
evaluation of during exercise, 501-504

Glucose metabolic imaging, for assessment of viability, 620

Goldin equation, noninvasive version of, 486

Great arteries, transposition of, 369-376
in infants with congenital heart disease, management of, 433-434
operative technique of, 372-373
physiologic and anatomic considerations in, 370-371
preoperative, operative, and postoperative management of, 371-372
results of, 373-375
surgical approach to, ventricular function following, 444-445

Heart, conduction system of, anatomy and physiology of, 301-302
developmental aspects of, 302
failing, mechanical behavior of, 25-30
pathophysiology of, 25-37
normal, metabolism of, 700-701

Heart failure, ACE inhibition in, 120-121
progress in, 119-130
activation of intrarenal hormones in, 53-54
afferent signals in, 50-51
cardiovascular risk factors for, modifiable, 6-7
chronic, digitalis for, 101-103
congestive. *See Congestive heart failure.*
coronary heart disease as cause of, 4
definition of, 11-12, 49, 87
digitalis and non-ACE inhibitor vasodilators in, 99-118
efferent mechanisms in, 51
eicosanoids in, 57
epidemiologic aspects of, 1-9
etiology of, 1-4
clinical, 4
exercise in, contrasting ventilatory and gas exchange patterns during, 46-47
excessive ventilation in, 41-44
hormones in, 56-57
incidence of, 1
increased renal tubular reabsorption of sodium in response to, 55-56
intrinsic risk factors for, 4-6
issue on, 1-204
kallikrein-kinin system in, 53-54
management of, beta-adrenergic blockade for, 174-179
cardiac transplantation for, 183-194
immunosuppression for, 171-174
methods for peripheral blood flow measurements in, 63-64
mild, use of ACE inhibitors in, 125-126
multivariate risk profile for, 7
pathogenesis of, 11-24
future directions in, 22
physiologic compensations during, 49-50
prevalence of, 1
prevention of, 7
prognosis of, 8
release of ADH in, 52, 57
release of ANF in, 52-53, 58-59
renal responses to, 55
renal sympathetics in, 57
renin-angiotensin system in, 51-52, 119-120
severity of, assessment of, 32-36
cardiac reserve in, 34
hemodynamic findings in, 33
signs and symptoms in, 32-33
ventricular diastolic dysfunction in, 33-34
ventricular systolic dysfunction in, 34
sodium retention in, 49-62
sympathetic nervous system in, 51

Heparin, in treatment of acute myocardial infarction, 834

High-pulse repetition frequency Doppler, 285

Hormonal systems, in CHF, 75-81
confounding factors in, 81-82
endocrine effects of, 75-77
paracrine/autocrine effects of, 80-81
renin-angiotensin-aldosterone system in, 77-78
vasopressin in, 78-80

Hormones, in heart failure, 56-57

Hydralazine, and nitrates, for chronic CHF, 111-113

Hypertension, as cause of cardiac failure, 4
in children, and coronary heart disease, 469
following heart transplantation, 416
pulmonary, toxin-induced, vascular development and, 899-900

Hypertrophy, patterns of, 14-16
physiologic vs. pathologic, 16

Hypolipidemic therapy, in prevention and treatment of restenosis, 858-859

Hypoplastic left heart syndrome, 377-385
anatomic definition of, 377
clinical features of, 379-380
developmental anatomy of patients with, 377-378
pathologic anatomy of patients with, 378-379
physiological considerations in, 379
surgery for, 380-384

Hypoxia, postnatal response to, effect of structural maturation of pulmonary arteries on, 899

I-123 meta-iodobenzylguanidine (MIBG), for cardiac imaging, 599-603
future directions for, 603

I-123 phenylpentadecanoic acid (IPPA), for cardiac imaging, 594-599

I-123 phenylpentadecanoic acid (IPPA) (Continued)
 future directions for, 598-599

Immunosuppression, clinical application of, in cardiac transplantation, 189-190
 in heart transplantation in children, 414-415
 for myocarditis, 171-174

Indiana Heart Institute, experience with PTCA in acute myocardial infarction, 842-844

Infarction, myocardial. See *Myocardial infarction*.

Infection, following heart transplantation in children, 415
 following surgery for congenital heart disease in infants, 435

Inotropic agents, positive, in heart failure, 131-144

Interventricular systolic pressure, Bernoulli equation for evaluation of, 279

Intravascular ultrasound, 525-536
 · Doppler catheters in, 525-530
 future directions of, 535
 two-dimensional imaging catheters in, 530-535

Ischemia, acute, detection of, PET for, 620-621
 chronic, detection of, PET for, 621-624
 effects on cardiac energy metabolism, 697-698
 identification of, MRS for, 701-703

Ischemic heart disease, NMR imaging for, 640-643

Kallikrein-kinin system, in heart failure, 53-54

Kawasaki syndrome, 453-465
 cardiac findings in, 455-456
 clinical course of, 461-463
 clinical features of, 454-455
 coronary arteriography in, 457-458
 coronary artery lesions resulting from, regression and evolution of, 461
 electrocardiography in, 456
 epidemiology of, 453
 etiology and pathogenesis of, 454
 management of, 458-460
 myocardial ischemia and infarction in, 461-462
 pathology of, 454
 spontaneous regression of aneurysms in, 462
 two-dimensional echocardiography in, 456-457
 without detectable coronary lesions, 462-463

Kidney(s), hemodynamics of, 55
 neurohormonal influences on, in CHF, 81
 physiology of, 54-55
 response to heart failure, 55

Laminar flow visualization, 261-262

Lasers, in prevention and treatment of restenosis, 859-860

Left ventricular assist systems (LVAS), electrical implantable, for cardiogenic shock patients, 198-199

Left ventricular diastolic function, ultrafast CT scanning for characterization of, 729-733

Left ventricular dysfunction, CABG for, operative mortality of, 819-822
 severe, PTCA for patients with, 813-825
 angioplasty data, 815-816
 complications of, 815, 817
 definition of, 814
 follow-up data, 814-815, 816
 future trends, 823-824
 life-table analysis, 817
 patient characteristics, 815
 patient selection, 813-814
 statistical analysis, 815

techniques of, 814

Left ventricular function, effect of thrombolytic agents on, in acute myocardial infarction, 829-830

Left ventricular hypertrophy (LVH), 5-6
 as cause of heart failure, 11

Left ventricular mass, cardiac edge detection for ultrafast CT in determination of, 723-724

Left ventricular outflow tract obstruction, operated on, long-term follow-up of, 919-920

Left ventricular wall stress, detection of, cine MRI for, 656-657

Levodopa, oral, in heart failure, 136

Lidocaine, for ventricular arrhythmias, 157
 in infants and children, 303-304

Lipid disorders, familial aggregation of, 468

Lipids, levels of, in children, 468
 role of, in coronary heart disease, 467
 tracking of, in children, 468

Lung, congestion of, pathophysiology of, 39-48

LVH. See *Left ventricular hypertrophy*.

Lymphoproliferative disease, following heart transplantation in children, 416

Magnetic resonance angiography, 674-681
 applications of, 680-681
 imaging strategies in, 677-680
 limitations of, 680

Magnetic resonance flow imaging, signal behavior in, 662-666

Magnetic resonance imaging (MRI), contrast-enhanced, for assessment of myocardial ischemia and infarction, 685-696
 for assessment of myocardial perfusion during ischemia, 692-694
 for assessment of reperfused infarcts and myocardial salvage, 691-692
 current applications of, 661-683
 fast, 674
 spin-echo, 666-669

Magnetic resonance imaging (MRI) signal intensity, and contrast enhancement, principles of, 686

Magnetic resonance phase display imaging, 669-674

Magnetic resonance spectroscopy (MRS), basic principles of, 698
¹³C, 707
 for detection of cardiac transplant rejection, 703-704
 for evaluation of cardiomyopathies, 703
 for evaluation of peripheral muscle metabolism, 707-709
¹H, 705-706
 of the heart, 697-712
 in human studies, 704-705
 for identification of ischemia and infarction, 701-703
 localization techniques of, 698-699
 phosphorus, 699-700
 sodium and potassium, 706-707

Marfan's syndrome, diagnosis of, NMR imaging for, 636

Maturational, acquisition of transverse tubular system in, 220-221
 and cardiac contractility, 209-225
 changes in cell organization and myofibrils during, 211-213
 changes in cytoskeleton during, 213-214
 effect on control of cytosolic calcium, 218-219
 role of sarcoplasmic reticulum in, 219-220
 changes in sarcolemma during, 221

Methotrexate, for prevention of allograft rejection in cardiac transplantation, 190

Mexiletine, for ventricular arrhythmias, 158
in infants and children, 304-305

Milrinone, for CHF, 138-139

Minoxidil, for chronic CHF, 113

MRS. See *Magnetic resonance spectroscopy*.

Multivariate risk profile, for cardiac failure, 7

Myocardial blood flow, quantitation of, PET for, 613-615

Myocardial contractility, definition of, 12-14

Myocardial function, regional, cine MRI for, 652-654

Myocardial infarction, acute, digitalis for, 100-101
effect on survival, adjunctive therapy, 833-834
bleeding complications of, 832-833
identification of, by contrast-enhanced MRI, 689-691

PTCA for, 837-851. See also *Percutaneous transluminal coronary angioplasty, for acute myocardial infarction*.

thrombolysis in, 837-838

thrombolytic therapy for, 827-836
characteristics of, 827, 829
clinical efficacy of, 829-832
mechanisms and properties of, 827-828

antimyosin scintigraphy in, 580-582

detection of, PET for, 615

identification of, by MRI without contrast agents, 685-686

MRS for, 701-703

in Kawasaki syndrome, 461-462

use of ACE inhibitors following, 125-126

Myocardial infarction shock, acute, circulatory assist devices for patients with, 200-201

Myocardial ischemia, detection of, by exercise ECG and thallium-201 scintigraphic markers, 565-575

identification of, by contrast-enhanced MRI, 687-689
by MRI without contrast agents, 685-686

oxidative metabolism in, detection of, PET for, 616-620

Myocardial perfusion, during ischemia, contrast-enhanced MRI for, 692-694

regional, ultrafast CT scanning for evaluation of, 717-723
basic flow algorithm, 718
in vitro and in vivo studies, 718-723

Myocardial salvage, coronary reperfusion in, assessment of, MRI for, 691-692

Myocarditis, antimyosin scintigraphy in, 582-583
clinical diagnosis of, 173
immunosuppression for, 171-174
animal studies, 172
human studies, 173-174
multicenter randomized trial, 174
in Kawasaki syndrome, 455

Myocardium, necrosis of, imaging of, 577-587
comparison of techniques, 583-586
radiolabeled antimyosin in, 578-583
Tc-99m-pyrophosphate in, 577-578

pathologic growth and remodeling of, 19-22
physiologic growth and remodeling of, 16-19
remodeling of, definition of, 14
ultrastructure of, 211-213

Myocyte(s), cardiac, pathologic growth of and remodeling, 19-20
physiologic growth of and remodeling, 16-18

Myofibrils, effect of maturation on, and cardiac contractility, 213

Myosin, effects of maturation on, 214-216

N-13 ammonia, for evaluation of myocardial blood flow, 609-610

Nephrotoxicity, following heart transplantation in children, 416

Neurohormonal influences, in pathogenesis of CHF, 73-86

Neurotransmitter system, in CHF, 73-75
confounding factors in, 81-82

Nifedipine, for chronic CHF, 114

Nitrates, in heart failure, 107-110
and hydralazine, for chronic CHF, 111-113
in treatment of acute myocardial infarction, 834

Nitroglycerine, in heart failure, 107-110

NMR imaging. See *Nuclear magnetic resonance imaging*.

Nuclear magnetic resonance (NMR) imaging, for aortic disease, 633-636
for cardiac and paracardiac masses, 637-639
in cardiac transplant rejection, 639-640
cardiovascular, 631-649
basic principles of, 631-632
instrumentation and safety, 632
physics and basic imaging techniques, 631-632
for cardiovascular morphology, 632
for congenital heart disease, 636-637
for ischemic heart disease, 640-643
for pericardial disease, 645
for quantitation of cardiac dimensions and ventricular functions, 632-633
for valvular disease, 643-645

O-15 labeled water, for evaluation of myocardial blood flow, 610

OKT*3, for prevention of allograft rejection in cardiac transplantation, 190

Orthotopic biventricular replacement prosthesis, for cardiogenic shock patients, 199

Paramagnetic contrast agents, 686-687

Patency, definition of, 829

Patent ductus arteriosus (PDA), catheter closure of, 351-360
case studies of, 358
clinical results of, 356-358
complications of, 359-360
delivery system of, 353-356
historical perspective, 351-352
technical considerations of, 352

Doppler echocardiography for evaluation of, 278-279
pulsed Doppler ultrasound for, 285-287

PDA. See *Patent ductus arteriosus*.

PDA occluder, for cardiac defects, 360-362
technical considerations of, 352

Pediatric cardiology, diagnosis of, role of Doppler echocardiography in, 265-297

Percutaneous balloon aortic valvotomy, for valvar aortic stenosis, in children, 341-345

Percutaneous balloon mitral valvotomy, for rheumatic mitral stenosis, in children, 345-346

Percutaneous transluminal coronary angioplasty (PTCA), 743-747
acute and chronic reactions to, 854-855
for acute myocardial infarction, 837-851
complications of, 840
Indiana Heart Institute's experience, 841-844
long-term vessel status following, 848
results of studies, 840-842
technique of, 839-840

Percutaneous transluminal coronary angioplasty (PTCA)
 (Continued)

- of coarctation and postoperative aortic obstructions, 346-347
- complications associated with, 743-744
- coronary angiographic patterns at site of, morphologic correlates of, 759-764
- effect on adjacent nondilated vessels, 753-755
- evolution of, 739-742
- intravascular stents in, 877-894. See also *Stents, intravascular*.
- issue on, 739-923
- mechanisms of, 853-854
- mechanisms of, 755-757
- mechanisms of recurrence following, 757-759
- multiple-lesion, definition of, 792
- in multivessel disease, 746, 771-782, 783-789
 - angioplasty data, 784-785
 - clinical characteristics, 784-785
 - complete versus incomplete revascularization in, 788
 - complications of, 784
 - follow-up procedures, 785
 - life-table analysis, 785-786
 - methods and materials, 783-784
- in patients older than 70 years, 805-812
- angioplasty data in, 807
- complications of, 806-807
- mortality and morbidity related to, 808-809
- patient characteristics, 806
- patient selection and methods, 805-806
- in patients with previous bypass surgery(ies), 744-745
- in patients with prior CABG surgery, 791-803
 - angioplasty data, 793, 799
 - clinical characteristics, 792-793, 799
 - complications of, 793, 797, 799-800
 - follow-up data, 792-794, 798, 800-801
 - life-table analysis, 794, 801
 - patient evaluation, 791-792
 - patient selection, 791
- in patients with severe left ventricular dysfunction, 813-825
- percutaneous cardiopulmonary support in, 865-875
- for peripheral pulmonary artery stenosis, in children, 335-339
 - complications of, 338-339
 - follow-up procedures, 339
 - procedure for, 335-336
 - results of, 336-338
- primary, versus thrombolytic therapy, for acute myocardial infarction, 844-847
- restenosis following, 853-864. See also *Restenosis*.
- in single-vessel disease, 745-746
- in treatment of obstructed aorto coronary saphenous vein bypass grafts, 764-769
- Pericardial disease, NMR imaging for, 645
- Pericardial effusion, in Kawasaki syndrome, 455
- PET. See *Positron emission tomography*.
- Phenytoin, for ventricular arrhythmias, in infants and children, 304
- Phosphodiesterase inhibitors, in heart failure, 136-140
 - long-term therapy with, 140-142
- Plaque compression, as result of TBA, 755
- Plaque fracture, as result of TBA, 755
- Positron emission tomography (PET), 607-629
 - for assessment of coronary artery flow reserve, 612-613
 - for assessment of tissue viability in ischemic heart disease, 624-625
 - basic principles of, 607-608
 - for detection of acute ischemia, 620-621
- for detection of chronic ischemia, 621-624
- for detection of coronary artery disease, 612
- for detection of myocardial infarction, 615
- for detection of oxidative metabolism in myocardial ischemia, 616-620
- for determining ischemic versus nonischemic cardiomyopathy, 615-616
- future prospects for, 625
- for quantitation of myocardial blood flow, 613-615
- tracers used in, to evaluate blood flow, 608-610
 - to evaluate myocardial metabolism, 610-612
- Postcardiotomy syndrome, following cardiac surgery, 435
- Postcardiotomy ventricular failure, circulatory assist devices for patients with, 199-200
- Prazosin, for chronic CHF, 110-111
- Pressure-volume loop, in assessment of chamber contractility, 27-29
- Probulin, in prevention and treatment of restenosis, 858
- Procainamide, for ventricular and supraventricular arrhythmias, in infants and children, 305-306
 - for ventricular arrhythmias, 158-159
- Propafenone, for arrhythmias, in infants and children, 312
- Proteins, contractile, role in myocardial contraction, 214-218
- Prourokinase, for acute myocardial infarction, reperfusion and patency of, 829
- PTCA. See *Percutaneous transluminal coronary angioplasty*.
- Pulmonary arteries, structural maturation of, effect on postnatal response to hypoxia, 899
- Pulmonary arterio-venous malformations, closure of, 366-367
- Pulmonary artery pressure, Doppler echocardiography for evaluation of, 276-282
- Pulmonary atresia, before and after Fontan procedure, 446-447
 - with intact ventricular septum, operated on, long-term follow-up of, 919
 - with intact ventricular septum (PA IVS), 387-397
 - with ventricular septal defects, operated on, long-term follow-up of, 918
- Pulmonary atresia with intact ventricular septum (PA IVS), definitive surgery for, 392-397
 - morphology of, 387-388
 - palliative surgery for, 388-392
- Pulmonary edema, effect on lung function, 39-40
- Pulmonary fibrosis, effect on lung function, 40
- Pulmonary hypertension, toxin-induced, vascular development and, 899-900
- Pulmonary stenosis, operated on, long-term follow-up of, 917
- Pulmonary vascular abnormalities, high-flow, high-pressure induced, 900-904
- Pulmonary vascular bed, cell culture systems in, 910
 - decreased pulmonary blood flow and structural changes in, 911
 - structure and function of, 895-914
- Pulmonary vascular changes, progressive, mechanism of, 905-907
- Pulmonary vascular congestion, effect on lung function, 39
- Pulmonary vascular development, and hyperoxia-induced abnormalities, 900
 - normal, 895
 - and toxin-induced pulmonary hypertension, 899-900
- Pulmonary vascular reactivity, increased, mechanism of, 904-905
- Pulmonary vascular resistance, drop in, at birth, 896
- Pulmonary vascular structure and function, abnormal perinatal, 896

Pulmonary vasculature, functional properties related to, at birth, 895-896

Pulmonary venous obstruction, structure and function of, 911

Pulmonary venous return, total anomalous, correction of, long-term follow-up of, 921

Pulsatile assist devices, external, for cardiogenic shock patients, 197-198

Quinidine, for ventricular and supraventricular arrhythmias, in infants and children, 305
for ventricular arrhythmias, 158

Regional left ventricular performance, during stress, assessment of, 504-505

Regurgitant index (RI), calculation of, by blood pool scintigraphy, 547-549
improved, blood pool scintigraphy for, 555

Remodeling, of myocardium, 14
pathologic capillary growth and, 20
pathologic cardiac fibroblast growth and, 20-22
pathologic cardiac myocyte growth and, 19-20
pathologic growth and, 19-22
physiologic capillary growth and, 18
physiologic cardiac fibroblast growth and, 18-19
physiologic cardiac myocyte growth and, 16-18

Renal sympathetic nerves, in heart failure, 57

Renin-angiotensin-aldosterone system, in CHF, 77-78
in heart failure, 56-57

Renin-angiotensin system, in heart failure, 51-52, 119-120
tissue, in heart failure, 120

Reperfusion, definition of, 829

Restenosis, definition of, 854
detection of, 856-857
factors affecting, 855-856
following PTCA, 853-864
mechanism of, 854
prevention and treatment of, 857-860
lasers, 859-860
mechanical devices, 859
pharmacologic agents, 857-859

Resuscitative devices, for cardiogenic shock patients, 196-197

Rheumatic fever, as cause of heart disease, 2-3

Right ventricular outflow tract obstruction, operated on, long-term follow-up of, 917-919

Right ventricular pressure, Doppler echocardiography for evaluation of, 276-282

Rubidium-82, for evaluation of myocardial blood flow, 608-609

Saphenous vein angioplasty, 764-769

Sarcolemma, changes in, during maturation, 221

Scintigraphy, blood pool, 537-563. *See also Blood pool scintigraphy.*

Semilunar valve regurgitation, Doppler echocardiography for evaluation of, 279-282

Shock, cardiogenic, reperfusion therapy in, 848

Shunts, left-to-right, operated on, long-term follow-up of, 915-917

Smooth muscle migration, mechanism of, 910-911

Sodium, increased renal tubular reabsorption of, in response to heart failure, 55-56

Sodium nitroprusside, in heart failure, 107-110

Sodium retention, in CHF, effects of neurotransmitter system on, 75
in heart failure, 49-62

Sotalol, for arrhythmias, in infants and children, 312

Stenosis, atrioventricular valve, Doppler echocardiography for assessment of, 276
peripheral arterial, Doppler echocardiography for assessment of, 283-285

peripheral pulmonary artery, in children, balloon angioplasty for, 335-339

pulmonary, operated on, long-term follow-up of, 917
rheumatic mitral, in children, percutaneous balloon mitral valvotomy for, 345-346

semilunar valve, Doppler echocardiography for assessment of, 273-276

subvalvar aortic, Doppler echocardiography for assessment of, 282

subvalvar aortic, discrete, operated on, long-term follow-up of, 919-920

supravalvar aortic, Doppler echocardiography for assessment of, 282

valvar aortic, in neonates, percutaneous balloon aortic valvotomy for, 342-343
percutaneous balloon aortic valvotomy for, 341-342

valvar pulmonary, in children, balloon valvuloplasty for, 331-335

valvar aortic, operated on, long-term follow-up of, 919

Stents, intravascular, 877-894
current indications for, 889-891
future directions in, 891-893
historical background of, 877-878
"ideal," 878-879
in prevention and treatment of restenosis, 859
types of, 879-889
nitinol, 879-880
self-expanding multifilament stainless-steel, 880-884
serpentine stainless-steel, 886-889
tubular stainless-steel, 884-886

Steroids, in prevention and treatment of restenosis, 858

Stiffness, active, definition of, 12
passive, definition of, 12

Streptokinase, for acute myocardial infarction, reperfusion and patency of, 829

anisoylated (APSAC), for acute myocardial infarction, reperfusion and patency of, 829

in treatment of acute myocardial infarction, effect on survival, 830

Stress, and elevated blood pressure, in children, 470-472
evaluation of, blood pool scintigraphy for, 555-558
exercise, assessment of, 499-500
regional left ventricular performance during, assessment of, 504-505

Stress echocardiography, 493-507
for assessment of types of stress, 499-500
diagnostic information gained from, 505-506
equipment in, 494-498
future directions in, 507
limitations of, 506-507
qualitative versus quantitative analysis in, 500-501
timing of imaging in, 498
views in, 498-499

Stroke volume imaging, blood pool scintigraphy for, 549

Sudden cardiac death, ventricular arrhythmias and, in CHF, 148-151

Sympathetic nervous system, in heart failure, 51
interaction of peripheral circulation with, 67-69

Systemic-to-pulmonary connections, closure of, 366

Systolic dysfunction, definition of, 14

Tachycardia, atrial ectopic, surgery for, in children, 323-324

junctional reciprocating, permanent form of, surgery for, in children, 322

Kent bundle, surgery for, in children, 319-322

supraventricular, AV node reentry, surgery for, 328

surgery for, in children, 319-324

surgery for, new techniques, in children, 327-328

ventricular, following tetralogy of Fallot, surgery for, in children, 326-327

incessant, surgery for, in infants, 324-325

surgery for, in children, 324-327

TAH. See *Total artificial heart*.

TBA. See *Balloon angioplasty, transluminal*.

Tc-99m CPI, for cardiac imaging, 590

Tc-99m isonitriles, for cardiac imaging, 589-594

future directions of, 594

Tc-99m MIBI, for cardiac imaging, 590-594

Tc-99m-pyrophosphate, for detection of cardiac myocardial necrosis, 577-578

Tc-99m TBI, for cardiac imaging. See 0

Terazosin, for chronic CHF, 111

Tetralogy of Fallot, in infants with congenital heart disease, management of, 433

operated on, long-term follow-up of, 917-918

surgical approach to, ventricular function following, 445-446

Thallium-201 myocardial perfusion scintigraphy, for detection of myocardial ischemia, 568-574

in asymptomatic subjects, 569-570

in patients recovering from acute myocardial infarction, 571-574

in stable symptomatic patients, 570-571

Thrombolytic agents, for acute myocardial infarction, 827-836, 837-838. See also *Myocardial infarction, acute, thrombolytic therapy for*.

Tissue plasminogen activator (t-PA), for acute myocardial infarction, disadvantages of, 827

effect on survival, 830-832

Tocainide, for ventricular arrhythmias, 157-158

Total artificial heart (TAH), as bridge to transplantation, 193

for cardiogenic shock patients, 199

Transesophageal echocardiography (TEE), ambulatory, indications for, 515-520

anatomic imaging views by, 513-515

future developments in, 522-523

intraoperative, indications for, 520-522

performance of, 512-513

Transesophageal echocardiography (TEE) probes, 511-512

Transplantation, cardiac, in children, 411-418

factors limiting long-term survival following, 415-416

patient selection in, 412-414

role of immunosuppression and allograft rejection in, 414-415

survival and quality of life following, 417

rejection of, MRS for detection of, 703-704

NMR imaging for, 639-640

Transposition of the great arteries, surgical management of, long-term follow-up of, 921

Transverse tubular system, acquisition of, in maturation, 220-221

Triclopiome, in prevention and treatment of restenosis, 858

Tricuspid atresia, before and after Fontan procedure, 446-447

Tricuspid regurgitation, Doppler echocardiography for evaluation of, 276-278

Trimazosin, for chronic CHF, 111

Tropomyosin, effects of maturation on, 216-217

Troponin T, effects of maturation on, 217-218

Turbulent flows, in pediatric congenital heart disease, 262

Two-dimensional imaging catheters, 530-535

Valvular disease, NMR imaging for, 643-645

Valvular regurgitation, detection of, cine MRI for, 654-656

Vascular graft injection, detection of, NMR imaging for, 635-636

Vascular tone, in CHF, effects of neurotransmitter system on, 73-75

Vasculature, peripheral, in conditioning process, evidence for participation of, 66-67

Vasoconstriction, hypoxic, in fetus and newborn, consequences of, 228-229, 896-899

Vasodilators, in chronic CHF, 110-115

in heart failure, 103-115

specific agents, 107-109

systemic and regional hemodynamic effects of, 105-107

positive, in heart failure, 131-144

Vasopressin, in CHF, 78-80

Venous occlusion plethysmography, for measuring blood flow to skeletal muscle, 63-64

Ventilation, excessive, during exercise in cardiac failure, 41-44

Ventilatory reserve, diminished, effect on lung function, 44-46

Ventriole(s), left, coupling of, with arterial circulation, 30-32

Ventricular diastolic dysfunction, in assessment of severity of cardiac failure, 33-34

Ventricular elastance, of failing heart, 26

Ventricular function, assessment of, by blood pool scintigraphy, 537-563

by echocardiography, 558-560

clinical assessment of, 440-443

diastolic, assessment of, by Doppler ultrasound, 271-272

of failing heart, 29-30

effect of birth on, 221-223

following surgery for congenital heart defects, 439-452

problems related to, 443-444

unresolved issues concerning, 447-449

following surgical approach to transposition of the great arteries, 444-445

following surgical repair of tetralogy of Fallot, 445-446

systolic, assessment of, by Doppler ultrasound, 269-270

of failing heart, 25-26

Ventricular resistance, of failing heart, 26-27

Ventricular septal defect, in infants with congenital heart disease, management of, 433

operated on, long-term follow-up of, 916

Ventricular septal defect flow imaging, 260-261

Ventricular systolic dysfunction, in assessment of severity of cardiac failure, 34

Verapamil, for supraventricular arrhythmias, in infants and children, 309

y
A
5
70
t
y